JNJ Quantitative Stock Analysis

Validea's guru fundamental report indicates Johnson & Johnson (JNJ), a large-cap growth stock in the Biotechnology & Drugs industry, received a 77% rating using Partha Mohanram's P/B Growth Investor model. This model, designed to identify low book-to-market stocks with sustained growth characteristics, places JNJ just below the 80% threshold typically signaling 'some interest.' While JNJ passed most growth-oriented criteria including return on assets and sales variance, it notably failed tests related to cash flow from operations to assets versus return on assets and research and development to assets.

Analysis

Based on Validea's guru fundamental report, Johnson & Johnson (JNJ) scores a 77% on the Partha Mohanram P/B Growth Investor model, placing it just below the 80% threshold that typically signals strategic interest. The model, designed to identify low book-to-market stocks with sustained growth potential, confirms that JNJ passes on several key fundamental metrics, including Return on Assets, Sales Variance, and Capital Expenditures to Assets. This indicates a profile of a stable, large-cap growth company. However, the analysis flags two notable weaknesses. JNJ fails the criteria for 'Cash Flow from Operations to Assets vs. Return on Assets' and 'Research and Development to Assets'. The first failure suggests that the company's cash generation may not fully support its reported profitability (ROA), a potential concern for earnings quality. The second failure is particularly significant for a firm in the Biotechnology & Drugs industry, as an insufficient R&D-to-assets ratio could imply underinvestment in its future product pipeline, a critical driver of long-term growth in the sector.

Key Decisions for Investors

• Investors may interpret the 77% score as a sign of fundamental stability but not a strong signal for new investment, as it falls short of the model's 80% interest threshold.
• It is prudent to conduct further due diligence on JNJ's research and development spending relative to its asset base and industry peers, as the model's failure on this point flags a potential risk to its long-term growth pipeline.
• The flagged discrepancy between cash flow and return on assets warrants a deeper investigation into the company's earnings quality and cash conversion cycle.